Eastern Bank Buys 24,600 Shares of Boston Scientific Corporation $BSX

Eastern Bank raised its stake in Boston Scientific Corporation (NYSE:BSX) by 9.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 293,178 shares of the medical equipment provider’s stock after purchasing an additional 24,600 shares during the quarter. Eastern Bank’s holdings in Boston Scientific were worth $28,623,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in Boston Scientific by 136.7% during the first quarter. Geneos Wealth Management Inc. now owns 3,423 shares of the medical equipment provider’s stock worth $345,000 after purchasing an additional 1,977 shares during the last quarter. Modern Wealth Management LLC grew its position in Boston Scientific by 7.9% in the 1st quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 218 shares in the last quarter. Parallel Advisors LLC increased its stake in Boston Scientific by 5.9% in the 2nd quarter. Parallel Advisors LLC now owns 16,370 shares of the medical equipment provider’s stock valued at $1,758,000 after buying an additional 911 shares during the last quarter. Finally, NBC Securities Inc. increased its stake in Boston Scientific by 3.9% in the 2nd quarter. NBC Securities Inc. now owns 12,598 shares of the medical equipment provider’s stock valued at $1,353,000 after buying an additional 472 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

Boston Scientific Trading Down 1.8%

Shares of BSX stock opened at $94.02 on Wednesday. The stock has a market capitalization of $139.37 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.69 and a beta of 0.67. The company’s fifty day simple moving average is $97.43 and its two-hundred day simple moving average is $100.58. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BSX shares. Barclays boosted their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Canaccord Genuity Group cut their price objective on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Robert W. Baird raised their target price on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $125.21.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.